The Phase 1b study is a double blinded, randomized, placebo controlled, parallel group design testing multiple doses of Xen-101 vs. placebo over 4-week period in 32 adults with BMI between 30 and 45 kg/m². The study is being conducted in Australia and safety, tolerability, and total body weight change at the 4-week endpoint will be the primary objectives. Pharmacodynamic effects, including microbiome composition, serum ketone levels, metabolic biomarkers, and changes in self-reported appetite and hunger will also be investigated.

“We’re confident that this study design will deliver proof-of concept body weight reduction results after 4-weeks of therapy in the background of already documented excellent safety and tolerability profile,” said Dr. Dennis Kim, President and CEO of Xeno Biosciences. “With a daily oral administration schedule and a novel and differentiated mechanism of action, we believe Xeno is well-positioned to demonstrate Xen-101 as a new, exciting, and sought-after drug candidate that can address the strong and remaining unmet needs in the obesity field.” The results of the Phase 1b study are expected by the end of 2024.

For more information about Xeno Biosciences please contact Dr. Dennis Kim at dk23@xenobiosciences.com.

About Xeno Biosciences Inc.
Xeno Biosciences Inc. is a privately held drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. Xeno is advancing its lead development candidate, XEN-101, to address the unmet need for an effective, well-tolerated, orally administered obesity treatment. With a new understanding of the underlying mechanism of action of Roux-en-Y Gastric Bypass Surgery (RYGB), Xeno has developed a substitute for gastric bypass in a daily oral pill. XEN-101 has been shown to have wide safety margins and high tolerability in initial clinical trials.

The securities sold in the aforementioned private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the aforementioned shares. In addition, this press release contains certain forward-looking statements regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and the company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625622967/en/